- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
- Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
- Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
- Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
As of last trade, Aldeyra Therapeutics Inc (ALDX:NAQ) traded at 4.02, 182.99% above the 52 week low of 1.42 set on Oct 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.90 |
---|---|
High | 4.04 |
Low | 3.86 |
Bid | 4.01 |
Offer | 4.02 |
Previous close | 3.94 |
Average volume | 522.05k |
---|---|
Shares outstanding | 58.90m |
Free float | 47.92m |
P/E (TTM) | -- |
Market cap | 232.05m USD |
EPS (TTM) | -0.6375 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 15:56 BST.
More ▼